We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
RingCentral
RNG
$5.32B
| $22.1M | 0.05% |
634,883
+112,342
| +21% | +$3.78M |
|
402
Louisiana-Pacific
LPX
$5.45B
| $21.8M | 0.05% |
259,413
+213,942
| +471% | +$15.4M |
|
403
Neurocrine Biosciences
NBIX
$16.7B
| $21.8M | 0.05% |
157,780
-67,127
| -30% | -$9.17M |
|
404
NovoCure
NVCR
$1.89B
| $21.7M | 0.05% |
1,389,058
-81,406
| -6% | -$1.2M |
|
405
VeriSign
VRSN
$26.6B
| $21.5M | 0.05% |
113,549
+27,628
| +32% | +$5.43M |
|
406
Oshkosh
OSK
$9.58B
| $21.4M | 0.05% |
171,518
-135,667
| -44% | -$15.1M |
|
407
Ares Capital
ARCC
$14.4B
| $21.2M | 0.05% |
1,019,915
-3,308,819
| -76% | -$67M |
|
408
VF Corp
VFC
$5.85B
| $21.2M | 0.05% |
1,383,631
+1,230,526
| +804% | +$19.8M |
|
409
iShares Russell Top 200 Growth ETF
IWY
$16.6B
| $21.1M | 0.05% |
108,300
+5,600
| +5% | +$1.05M |
|
410
IDEAYA Biosciences
IDYA
$3.53B
| $21.1M | 0.05% |
479,921
+409,452
| +581% | +$17.6M |
|
|
VRN
411
DELISTED
Veren
VRN
| $21M | 0.05% |
2,567,595
-316,042
| -11% | -$2.21M |
|
412
PUT
Blackstone Mortgage Trust
BXMT
$2.38B
| $20.8M | 0.05% |
1,042,800
-82,300
| -7% | -$1.66M |
|
413
Allegion
ALLE
$14.4B
| $20.7M | 0.05% |
153,665
+88,833
| +137% | +$11.4M |
|
414
Archer Daniels Midland
ADM
$37.2B
| $20.7M | 0.05% |
329,311
+312,298
| +1,836% | +$18.3M |
|
415
Corcept Therapeutics
CORT
$11.9B
| $20.6M | 0.05% |
818,475
+340,918
| +71% | +$8.05M |
|
|
ALPN
416
DELISTED
Alpine Immune Sciences Inc
ALPN
| $20.6M | 0.05% |
519,971
+141,558
| +37% | +$4.18M |
|
417
Qiagen
QGEN
$8.72B
| $20.4M | 0.05% |
461,424
+412,288
| +839% | +$18.8M |
|
418
Huntsman Corp
HUN
$1.8B
| $20.4M | 0.05% |
782,720
-104,387
| -12% | -$2.59M |
|
419
J.M. Smucker
SJM
$12.9B
| $20.1M | 0.05% |
159,871
-26,209
| -14% | -$3.32M |
|
420
CarMax
KMX
$8.28B
| $20.1M | 0.05% |
230,836
+40,658
| +21% | +$3.08M |
|
|
GES
421
DELISTED
Guess Inc
GES
| $19.8M | 0.05% |
629,472
-89,209
| -12% | -$2.2M |
|
422
Kanzhun
BZ
$7.36B
| $19.8M | 0.05% |
1,129,789
+855,606
| +312% | +$13.5M |
|
423
Hexcel
HXL
$7.77B
| $19.8M | 0.05% |
271,517
+133,232
| +96% | +$9.59M |
|
424
RxSight
RXST
$255M
| $19.8M | 0.05% |
383,131
+102,819
| +37% | +$5.05M |
|
425
Texas Roadhouse
TXRH
$13.6B
| $19.7M | 0.05% |
127,267
+113,267
| +809% | +$15.5M |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.